Accumen has acquired three companies this year, allowing it to generate significant additional value for hospitals and health system, commercial laboratory, and health plan clients
Accumen Inc., the leader in healthcare performance, today announced the launch of its new website at www.accumen.com.
When the company was founded eight years ago, it focused on improving laboratory performance. Its focus has broadened significantly since then as Accumen now works directly with hospitals and health systems, commercial labs and health plans to optimize all facets of healthcare performance. It helps to improve operational efficiencies, clinical outcomes and data performance. Those enhanced capabilities are described in detail on its new website.
“Accumen is following such a vibrant growth trajectory that we felt it was important to take time to share our company vision with current and future clients so they can see where we are headed and how our latest acquisitions fit into that picture. Accumen has purchased three companies this year in different healthcare service areas and we anticipate even stronger growth in 2020,” said Accumen President and CEO Jeff Osborne.
“As a result, wewanted our website to clearly describe the many new ways in which we can partner with hospitals and health systems, commercial labs, and health plans to deliver performance improvements throughout their businesses. I am proud to report that Accumen team members are now working with our clients across 34 states.”
“Our new website has a more consistent look and feel, better illustrating how the work we do delivers tangible outcomes for clients and a positive impact to healthcare overall,” added Accumen Chief Marketing Officer Kimberly MacDowell. “While our new Accumen website is already content rich, we will be adding new elements regularly, including case studies, healthcare education, podcasts, and our recorded webinar series.”
Accumen’s resources include a team of subject matter experts drawn from all areas of the healthcare industry, who are frequently asked to present on performance-related topics to organizations in ancillary and clinical service areas. It also has access to the renowned clinicians who comprise its Medical Advisory Council and regularly work with its clients and teams.
The three companies that Accumen acquired this year are Halfpenny Technologies Inc., a provider of clinical data exchange platforms for health systems, commercial labs, and health plans; Patient Readiness Institute’s MyBloodHealth®, a virtual, pre-operative anemia management solution; and 3DR Laboratories, the largest 3D medical image post-processing laboratory in the United States.
. About Accumen Inc.
At Accumen, our focus is healthcare performance. Accumen utilizes healthcare technology along with our expert performance team members to drive significant value to hospital, health system, commercial laboratory and health plan clients, providing strategic solutions, services and technology that deliver sustainable performance improvements in operations, clinical services, and data management. These offerings include lab and imaging transformation, consulting, supply chain optimization, lab outreach, patient blood utilization, test utilization, anemia management and clinical data exchange. Accumen’s offerings enable its clients to achieve and exceed their cost, quality, and service targets, as well as deliver excellent patient care through evidence-based data and clinical decision support capabilities.
We share the belief that performance matters. We are inspired to improve operational, clinical, and data performance across the healthcare industry because transformational change will make healthcare better for our clients, our communities and our families.
For more information, visit Accumen.com.
Disclaimer: Accumen has no authority, responsibility, or liability with respect to any clinical decisions made by – or in connection with – a provider’s laboratory, patient blood management, or other operations. Nothing herein and no aspect of any services provided by Accumen is intended – or shall be deemed – to subordinate, usurp, or otherwise diminish any providers’ sole authority and discretion with respect to all clinical decision-making for its patients.